CollPlant announces Commencement of Commercial Treatments of Vergenix®FG Wound Filler in Europe

Ness Ziona, Israel, August 10th , 2016 CollPlant Ltd. (TASE: CLPT), a regenerative medicine company focused on developing and commercializing tissue repair products based on its proprietary plant-based rhCollagen technology, announced the commencement of commercial treatments of Vergenix®FG (Flowable Gel) wound filler in patients in Italy.

The first patients were treated in the last two weeks at several hospitals in Italy. Initial feedback from the treating physicians was very positive.

Yehiel Tal, Chief Executive Officer of CollPlant, stated: “CollPlant has met an important milestone with the commercial launch of Vergenix®FG in Italy and we are actively seeking to expand our distribution network in Europe”.

About CollPlant

CollPlant is a clinical-stage regenerative medicine company focused on developing and commercializing tissue repair products based on its proprietary plant-based rhCollagen technology, initially for the orthobiologics and advanced wound care markets. The Company’s technology is designed to generate and process proprietary recombinant human collagen (rhCollagen), among other patent-protected recombinant proteins. Given that CollPlant’s rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response. The Company’s broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: Vergenix™STR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; Vergenix™FG (Flowable Gel) wound filler, for treatment of acute and chronic wounds, and; Vergenix™BVF (Bone Void Filler), for use in spinal fusion procedures and trauma. CollPlant’s business strategy includes proprietary development and manufacturing of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacturing and marketing of additional products.

For more information about CollPlant, visit http://www.collplant.com

Contact at CollPlant:
Eran Rotem
Chief Financial Officer
Tel: + 972-73-2325600/612
Email: Eran@collplant.com

Contact at Rx Communications Group, LLC
Paula Schwartz (for US Investors)
Senior Vice President
Tel: 917-322-2216
Email: pschwartz@RxIR.com

® 2015 CollPlant Ltd. All rights reserved. Version: CPW 02-16